Signature_________________________Date________ HARRY A. CROFT, MD Distinguished Life Fellow - American Psychiatric Association 8038 Wurzbach Rd., Suite 570 San Antonio, Texas 78229 210-692-1222 Email: hacmd@aol.com Website: www.drcroft.com PRESENT POSITIONS Medical Director, San Antonio Psychiatric Research Center, Founded 1986, San Antonio, Texas Private Psychiatry Practice, The Croft Group, PA, Founded 1976, San Antonio, Texas Medical Director, HealthyPlace.com , 2007-Present Host Weekly HealthyPlace TV Webcast, March 2009-March 2010 OTHER PRESENT WORKS (book): Harry Croft & Chrys Parker, authors: I ALWAYS SIT WITH MY BACK TO THE WALL: Managing Traumatic Stress and Cpmbat PTSD Through the RECOVER Approach for Veterans and Families, Stillpoint Media, 2011. PERSONAL INFORMATION Born: July 2, 1943; Houston, Texas Married: 1964 to present with 2 children born in 1966, 1977, and 3 granddaughters WORK HISTORY Private Clinical Psychiatric Practice: 1976 to present Medical Director, SA Psychiatric Research Center, 1985-present Medical Director, HealthyPlace.com, 2007 - present Military: 1973 to 1976 - Major, Army Medical Corps, Brooke Army Medical Center, San Antonio, Texas; Chief, Mental Health Clinic; Medical Director, Drug & Alcohol Program; Lecturer, Academy of Health Sciences; Recipient, US Army Meritorious Service Medal EDUCATION University of Texas Medical Branch, Galveston, Texas 1970 - 1973 - Residency, General Psychiatry 1969 - 1970 - Partial Residency, Obstetrics & Gynecology 1964 - 1968 – MD degree Brackenridge Hospital, Austin, Texas 1968 - 1969 - Internship, General Rotating Southern Methodist University, Dallas, Texas 1964 – BS Degree in Biology CERTIFICATIONS & LICENSURE DISTINGUISHED LIFE FELLOW, American Psychiatric Association, 2003 FELLOW, American Psychiatric Association, 1993 Diplomate in Psychiatry, American Board of Psychiatry & Neurology, 1979 Diplomate, American Board of Addiction Medicine, 2009 Certified Addictionist, American Society of Addiction Medicine, 1990 Diplomate in Sex Therapy, American Assoc. of Sex Educators, Counselors & Therapists, 1976 Medical License, Texas State Board of Medical Examiners, 1968, D4968 SPECIAL TRAINING IN SEXUALITY Masters & Johnson Institute, 1973 Stan Kaplan, Ph.D., Albuquerque, New Mexico, 1972 National Sex Forum, San Francisco, California, 1972 MEMBERSHIP IN PROFESSIONAL SOCIETIES American Medical Association, Texas & Bexar County Branches (AMA) American Psychiatric Association, Texas & Bexar County Branches (APA) American Society of Addiction Medicine (ASAM) American Association of Sex Educators, Counselors & Therapists (AASECT) American Society for Clinical Hypnosis (ASCH) American Society for Clinical Psychopharmacology (ASCP) Titus Harris Psychiatry Society National Medical Speakers Association (NSA) National Association of Physician Broadcasters (NAPB) American Academy of Radio and Television Health Communicators Society for the Scientific Study of Sexuality (SSSS) International Society for the Study of Women’s Sexual Health (ISSWSH) International Society for the Study of Trauma HOSPITAL STAFF ACCREDITATION Southwest Texas Methodist Hospital (Active Staff), 1976-2000 Southwest Texas Methodist Hospital (Courtesy Staff), 2000-present ACADEMIC TEACHING EXPERIENCE CME Faculty: Medical World Conferences, Duke PsychCME, Primary Care Network, Center for Medical Knowledge, Intellyst, Medical Knowledge (Psych Update, and PriMed) (To Present) Teaching Consultant, USAF Psychiatry Training Program, Texas Academy of Family Practice Wilford Hall Medical Center, 1973 - 1976 Clinical Assistant Professor, Psychiatry & OB-GYN, University of Texas Health Science Center at San Antonio, 1973 - 1976 Assistant Professor, Health Science, Baylor University, Waco, Texas, 1975 - 1976 Instructor, Academy of Health Sciences, Fort Sam Houston, Texas, 1973 - 1976 HONORS DISTINGUISHED LIFE FELLOW, American Psychiatric Association, 2003 Recipient of Physician's Recognition Award, AMA Recipient of The Meritorious Service Medal, U.S. Army Recipient of Special President's Award, The American Psychiatric Association, 1991 2 Recipient of THE WELBY AWARD FOR MEDIA EXCELLENCE, The Academy of Radio and TV Health Communicators Recipient of The Jules Bergman Award (BROADCASTER OF THE YEAR), The National Association of Physician Broadcasters, 1995 Recipient of Media Award, The American Psychiatric Association, 1996 Recipient of NATIONAL MEDIA AWARD, The National Mental Health Association, 1996 Heart Survivor Honoree, The American Heart Association, 2003 Biography: WHO’S WHO IN AMERICA (since 1976), Who's Who in Professional Speaking MEDIA WORK Weekly medical/psychiatric consultant, Trey Ware Show, KTSA am 55 radio (morning drive) 2005-present Psychiatric Correspondent, KMOL TV 4 (NBC Affiliate), January 1999 to March 2000 Monthly guest consultant SA Living 2000-present Psychiatric Correspondent with weekly features at 5pm & 10pm on KENS TV 5 (CBS affiliate), January 1988 to January 1999 Radio Show Host, PSYCH TALK, 2 hour live talk show, KENS Radio, January 1996 to December 1998 Selected to be Psychiatric Correspondent, VOICE OF AMERICA, daily news segment, 1997, psychiatric Correspondent on Kaleidoscope, National TV Morning Magazine, PAX TV, 2002 ABC TV affiliate (KSAT TV12), San Antonio regular (weekly) live and taped segments, 5pm News, September 1986 to January 1988 Appearances on: CBS Early Morning with Bryant Gumble, CNN News, Sonya Live Interviews: USA Today, Chicago Tribune, Bloomberg, CBS, CNN Radio, Texas Radio Network, The New York Times, The Associated Press, The Readers Digest, Better Homes & Gardens, National Public Radio, Canadian Broadcasting, Radio Interviews (100) including Philadelphia, Chicago, Houston, Dallas, Miami, and Los Angeles MAJOR WORKSHOPS & PRESENTATIONS The American Medical Association The American Psychiatric Association The American Society of Clinical Psychopharmacology The European College of Neuropsychopharmacology The Society of Biological Psychiatry The National Society for the Scientific Study of Obesity The American College of Obstetrics & Gynecology The American Association of Marriage & Family Counselors The Southern Medical Association The Texas Medical Association The National Army Chaplain's Association The National Army Social Work Association Retail Pharmacists of America The American Farm Bureau Jewish Women’s International Conferences Lectures Given to Psychiatrists, Primary Care Physicians, Neurologists, Mental Health Professionals, OB-Gyns, and other professional groups in: ALL OF THE 50 United States, & London, Paris, Amsterdam, San Juan, St Thomas, Monterrey, Toronto, Madrid Member of Distinguished Faculty for the following CME providers: PsychCME (Duke Psychiatry), Primary Care Network (PCN), Medical World Conferences, Prime MD Net, Texas Association of Family Practice 3 Curriculum development: Primary Care Network Lecture TopicsPhysicians & MH Professionals: Managing.Unipolar to Bipolar Depression Spectrum Depression-Long Term Treatment & Challenges Advances in Antidepressant Treatment Evaluation and Treatment of Adult ADHD, Treatment of Anxiety Disorders, Alcohol and Drug Abuse & Dependence Disorders Treatment of Medication Induced Sexual Dysfunction Treatment of Erectile.Dysfunction, Female Sexual Health Management of Insomnia General Public: Depression: Finding Light at the End of the Tunnel, Dealing with Anxiety, Lessons from the Heart (about heart disease), Keeping the Flame Alive (improving relationships and sex), Adult AHD, Substance Abuse PAPERS, POSTERS, PRESENTATIONS: Clayton, A, Croft HA, Handiwala L, “Antidepressants and Sexual Dysfunciton: Mechanisms and Clinical Implications,” Journal of Sex and Marital Therapy, 2012 (in print). Leibowitz M, Croft H et al, “The Safety and Tolerability Profile of Vilazodone, A Novel Antidepressant for the Treatment of Major Depressive Disorder, Psychopharmacology Bulletin, Vol 44, No. 3, 2012 Croft,H, “ Viibryd (vilazodone hcl): A New Option for the treatment of adults with MDD: An overview of Prescribing Information,” Product Theater Presentation, Annual Meeting of the American Psychiatric Association, Honolulu, May 2011 Croft, H et al, “The Safety and Tolerability Profile of Vilazodone in Patients with Major Depressive Dissorder,” Poster Presentation at the US Psychiatric Congress, San Diego, 11/2010. Sheehan, DV, Croft, HA et al. “Extended Release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study,” Psychiatry (Edgmont), 2009 May; 6(5): 20-33. Croft,H, Montejo,AL, Salazar-Fraile,J. “Bupropion: Tolerability and Safety,” Actas Esp Psiquiatr (SPAIN) 2008:36 (Supp 4). Nurnberg, GN, Hensley, PJ, Croft, HA, Debattista, CA, et al “Sildenafil Treatment of Women with Antidepressant-Associated Sexual Dysfunction: A Randomized Clinical Trial,” JAMA, July 23/30, 2008 (Vol 300): No 4, 395-404 Seagraves, Clayton, Croft, et al “A Multicenter Double Blind Placebo Controlled Study of Bupropion XL in Females with Orgasm Disorders” Poster at Psychiatric Congress 06, New Orleans, 11/06. Croft,HA “Physician Handling of Prescription Stimulants (CME Article)”, Pediatric Annals 35:8, 557-562, August, 2006. Clayton, A, Croft HA et al, “Bupropion XL Compared with Escitalopram: Effects on Sexual Functioning and Antidepressant Efficacy in Two Randomized, Double-Blind, Randomized Clinical Studies Journal of Clinical Psychiatry 67:5 735-746, May, 2006. 4 Croft, HA “Physician Handling of Prescription Stimulants (CME Article)” Psychiatric Annals 35:3 221-226 2005 Wornock JK, Clayton AH, Croft HA, Segraves RT, Biggs CF. Comparison Of Androgens IWomen With Hypoactive Sexual Desire Disorder: Combined Oral Contraceptive Pill Users vs NoCombined Oral Contraceptive Pill Users. Oral presentation at the International Society for The Study of Women's Sexual Health (ISSWSH) Annual Meeting, Atlanta, GA, October 28-31, 2004. Journal of Sex & Marital Therapy (In Print, 06) Seagraves, RT, Clayton, A, Croft, HA et al, “Bupropion Sustained Release for the Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women,” J Clin Psychopharmacology; 2004, 243) 339-342. Seagraves, RT, Clayton, A, Croft, HA et al, “Multicenter Study of Bupropion in Female Hypoactive Sexual Desire Disorder, “ Presented at2003 Annual Meeting of the International Society for the Study of Women’s Sexual Health, Amsterdam, the Netherlands. October, 2003. Labbate, L, Croft,HA, and Oleshansky, MA, “Antidepressant-Related Erectile Dysfunction:Management via Avoidance, Switching Antidepressants, Antidotes, and Adaptation,” J Clin Psychiatry, 2003; 64 (10): 11-19. Nurnberg HG, Hensley PL, Croft HA, Fava M, Warnock JK, Pain S. Sildenafil citrate treatment for SRIassociated female sexual dysfunction. Accepted for poster presentation at the 156 th American Psychiatric Association Annual Meeting, May 17-22, 2003, San Francisco , CA. Clayton, A, Pradko, J, Croft, HA, et al. “Prevalence of Sexual Dysfunction Among Newer Antidepressants,” J Clin Psychiatry, 2002; 63 (4): 357-366 Nurnberg H, Hensley P, Fava M, Croft HA, Gelenberg A, Wornock J, Shabsogh R, “Sildenafil for Serotonin Reuptake Inhibitor-Antidepressant Associated Female Sexual Dysfunction,” Presented at New Clinical Drug Evaluation Unit (NCDEU) annual meeting, Boca Raton, 2002 Croft, HA, Houser, T, Jamerson B, Leadbetter R, “Effect on Body Weight of Bupropion SR in Patients with Major Depression Treated for 52 weeks,” Clinical Therapeutics,24(4),April 2002 Segraves, R.T., Croft, H.A., Kavoussi, R., Ascher, J., Batey, S., et al. “Bupropion sustained release for the treatment of hypoactive sexual desire disorder in nondepressed women.” Journal of Sex and Marital Therapy, 2001; 27 (3) : 301-316 Croft, HA, “The Patient with Depression: Managing Compliance and Side Effects” Profiles in Depression, (Oxford Institute for Continuing Education), March 2002 Segraves, R.T., Croft, H.A., Kavoussi, R., Ascher, J., Batey, S., et al. “Bupropion sustained release for the treatment of hypoactive sexual desire disorder in nondepressed women,” Journal of Sex and Marital Therapy, 27(3): 303-316. 2001 May-June Croft, HA Settle, E, Houser T Batey, SR et al. “A Placebo Controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline,” Clinical Therapeutics, 21(4): 643-658, 1999 April Croft HA, Asher J, Batey S et al. “A comparison of burprion SR, Sertraline and placebo in depressed outpatients,” Biological Psychiatry, 45(8 supp) 75s, 1999 Croft H, Houser T Leadbetter R, Jamerson B, Metz A. Effects of bupropion sr on weight in the long-term treatment of depression. Obesity Research, 8 (Suppl. 1:10S), 2000 Croft H, Houser TL, Leadbetter R, Jamerson B, Metz A. Effects of bupropion sr on weight in the long term treatment of depression. Biological Psychiatry 49(Suppl 8:36s) 2001 Croft, H.A., Batey, S., Ascher, J., et al. 5 “A Comparison of the Effects of Bupropion SR and Sertraline on Sexual Functioning in Depressed Outpatients”, Poster Presented at Annual Meetings of: American Society of Clinical Psychopharmacology, St. Thomas, Virgin Islands, February 1999; Society of Biological Psychiatry, Washington, DC, May 1999; The American Psychiatric Association, Washington, DC, May 1999, European College of Neuropsychopharmacology, London, UK, September 1999 Kaats, G.R., Keith, S.C., Croft, H.A., Pullin, D., Squires, W., Wise, J.A. “Dietary Supplements and Behavior Modification Plan to Improve the Safety and Efficacy of Pharmacotherapy”, Advances in Therapy, 1998; 15: 165-177 Kaats, G.R., Wise, J.A., Blum, K., Morin, R.J., Adelman, J.A., Craig, J., Croft, H.A. “The Short –Term Therapeutic Efficacy of Treating Obesity with a Plan of Improved Nutrition and Moderate Caloric Restriction”, Current Therapeutic Research, 1996; 51: 261-274 Szekely, B. & Croft, H.A. "Effect of Naproxen Sodium on Perimenstrual Headache and Other Perimenstrual Symptoms: A Double -Blind, Placebo Controlled Study," American Journal of Gynecologic Health, Vol.V, #4,July/August 1991 Szekely, B. & Croft, H.A. "Prophylactic Effects of Naproxen Sodium on Perimenstrual Headache," Cephalalgia, International Journal of Headache, Vol. 19, Supp. 10, 1989 Szekely, B. & Croft, H.A. "Descriptive Characteristics of Women with Perimenstrual Headache," Headache, The Journal of Head & Face Pain, Vol. 29, #5, 1989 Levinson, A.J. & Croft, H.A. "Patients' Sexual Problems-Aspects of Physicians' Qualifications & Management," The Journal of Reproductive Medicine, Vol. 18, #1, January 1977 Croft, H.A. "How to Refer Your Patients to a Psychiatrist Without Hurting Their Feelings," Resident & Staff Physician Medical Times, August, 1976 Croft, H.A. "Managing Common Sexual Problems," Post Graduate Medicine, 4 Part Series, 1976: "Sexual History Taking," Vol. 60, #3, Sep. 1976., "Causes of Sexual Dysfunction," Vol. 60, #4, Oct.1976., "A Multilevel Treatment Model - Levels 1 & 2," Vol. 60, #5, Nov. 1976., "A Multilevel Treatment Model - Levels 3 & 4," Vol. 60, #6, Dec. 1976 Croft, H.A., et al. "Viewpoints," Medical Aspects of Human Sexuality, 129: 57-62, 1976 Croft, H.A. "The Sexual Information Examination," Journal of Sex & Marital Therapy, Vol. 1, #4, 319-325, 1976 Croft, H.A. "A Human Sexuality Course in the Military," Military Medicine, 141:104-108, 1976 Powell, L.C., Blakeney, P., & Croft, H.A. "Rapid Treatment Approach to human sexual inadequacy," American Journal of Obstetrics Gynecology,119:89, 94, May 1974 Dawson, E.B., Croft, H.A., Clark, R.R., & McGanity, W.J. "Study of Nine Cation Levels in Term Placentas -- Changes Associated with Toxemia of Pregnancy and Fetal Maturity," American Journal of Obstetrics & Gynecology, 103:8, April 1969 Dawson, E.B., Croft, H.A., Clark, R.R., & McGanity, W.J. "Study of Seasonal Variations in Nine Cations of Normal Term Placentas, "American Journal of Obstetrics & Gynecology, 102:3, October 1968 6 RESEARCH Trimel Biopharma SRL, Phase II-XXX-X-XXX-XXXX-XX- “A placebo-controlled, randomized, double-blind, parallel-group dose finding trial to evaluate the efficacy and safety of XXX-X Intranasal Testosterone Gel in pre-menopausal women with acquired Female Orgasmic Disorder.” -2012 Takeda XX XXXXXXX_XXX- “A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Flexible-Dose Study Evaluating the Effect of XX XXXXXXX vs Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder Experiencing Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction.” -2011 Otsuka XXX-XX-XXX- “A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed-dose XXX-XXXXX as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder, the Pyxis Trial.” -2011 Forest XXX-XX-XX- “A Double-blind, Placebo-Controlled, Fixed-Dose Study of XXXXXXXXX XX in Patients With Major Depressive Disorder.” -2011 Bristol-Myers Squibb XXXXX-XXX- “A Multicenter, Double-Blind, 58-week Rollover Study to assess the Safety and Tolerability of BMS-XXXXXX in Patients with Treatment Resistant Major Depression.”-2011 Bristol-Myers Squibb XXXXX-XXX- “A Multicenter, Randomized, Double-blind, Active-Controlled Study of the Efficacy and Safety of Flexibly-Dosed BMS-XXXXXX in Patients with Treatment Resistant Major Depression.” -2011 Takeda XX XXXXXXX_XXX- “A Phase 3, Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of XX XXXXXXX (XX and XX mg) in Subjects With Major Depressive Disorder.” -2010 Takeda XX XXXXXXX_XXX- “A Phase 3, Randomized, Double-Blind, Parallel-Group, PlaceboControlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (XX and XX mg) of XX XXXXXXX in Acute Treatment of Adults With Major Depressive Disorder.”2010 Forest XXX-XX-XX- “A Multicenter, Randomized, Double-blind, Placebo-Controlled, RelapsePrevention Study With XXXXX XX in Patients With Major Depressive Disorder.” -2010 Boehringer Ingelheim Protocol XXX.XXX- “A twenty-eight week, open-label, safety, extension trial of XXXXXXXXX XXX milligrams daily in premenopausal and naturally postmenopausal women with hypoactive sexual desire disorder in North America.” -2010 Boehringer Ingelheim Protocol XXX.XXX- “A twenty-four week, randomized, double-blind, placebo controlled, safety and efficacy trial of XXXXXXXX (XXX milligrams) administered orally once daily in premenopausal women with hypoactive sexual desire disorder in the United States.”- 2009 Boehringer Ingelheim Protocol XXX.XXX- “A 12-week, randomized, double-blind, placebo-controlled, Phase III safety trial of XXXXXX tablets (XXX milligrams daily) in women taking a XXXXXXXXXXX or XXXXXXXXXXXX with decreased sexual desire distress.” – 2009 Forest XXX-XX-XX- “A Double-Blind, Placebo-Controlled Study of XXXXXXXX (XXX-XXX) as Adjunctive Therapy in Major Depressive Disorder.” -2009 7 Forest XXX-XX-XX- “A Long-Term, Open-label Extension Study of XXXXX XX in Adult Patients With Major Depressive Disorder.”- 2009 Forest XXX-XX-XX- “A Double-blind, Placebo-Controlled, Fixed-Dose Study of XXXXX XX in Patients with Major Depressive Disorder.” -2009 GlaxoSmithKline XXXXXXXXX- “A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of XXXXXXX in Subjects with Major Depressive Disorder.” -2009 Eli Lilly XXX-XX-XXXX(X)- “A Randomized, Double-Blind Comparison of XXXXXXXXX and Placebo and Long Term Treatment with XXXXXXXXX in Adult Patients with Major Depressive Disorder.” 2009 Takeda XX XXXXXXX_XXX- “A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of a Single Dose of XX XXXXXXX in Acute Treatment of Adults with Generalized Anxiety Disorder.” -2008 Forest XXX-XX-XX- “A Long-Term, Open-Label Extension Study of XXXXXXX in Adult Patients with Major Depressive Disorder."- 2008 Forest XXX-XX-XX- “A Double-Blind, Fixed-Dose Study of XXXXXXX in Adult Patients with Major Depressive Disorder.”- 2008 Synosia Therapeutics XXXXXX-XXXX- “A Multi-center Randomized, Double-Blind, PlaceboControlled, Phase 2, Exploratory Study to Evaluate the Effect of XXXXXXXX on Anxiety in Patients with Moderate to Severe Generalized Anxiety Disorder.”- 2008 Sepracor XXX-XXX- “A Double-Blind, Randomized, Placebo Controlled, Multi-Center Study Examining the Efficacy and Safety of XXX-XXXXXX in Subjects with Generalized Anxiety Disorder.”2007 PGxHealth XXXX-XX-XX-XX- “A One Year Label Study Assessing the Safety and Tolerability of XXXXXX in Patients with Major Depressive Disorder.”- 2007 Labopharm XXXXXXX- “A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of XXXXXXXXXX and Placebo in the Treatment of Unipolar Major Depressive Disorder.”2007 Bristol-Myers Squibb XXXXXXXX- “A Multicenter, Randomized, Double-Blind, Placebo and Escitalopram Controlled Trial of the Safety and Efficacy of XXXXXXXX in the Treatment of Outpatients with Major Depressive Disorder”-2007 Boehringer Ingelheim Protocol XXXXXXX- “A twelve month, open-label, safety trial of XXXXXXX 50 milligrams to XXX milligrams daily in women with Hypoactive Sexual Desire Disorder.”-2007 Boehringer Ingelheim Protocol XXXXXXXX-“A Twenty Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of XXXXXXXX XX mg Twice Daily and XX mg Once and Twice Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder in North America.” - 2006 Astrazeneca Protocol XXXXXXX-“A Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of XXXXXXXX as Monotherapy in the treatment of Patients with Major Depressive Disorder.” -2006 AstraZeneca Protocol XXXXXXX-“A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of XXXXXXX Compared with Placebo in the Treatment of Generalized Anxiety Disorder.”- 2006 8 Sanofi-aventis Protocol XXXXXXX-“A Comparison of XXXXXX vs. Placebo in the Treatment of Insomnia Associated with Newly Diagnosed Major Depressive Disorder (MDD) or Untreated MDD Relapse, When Used Concomitantly with XXXXXXX.”-2006 Sanofi-aventis Protocol XXXXXXX-“A Comparison of XXXXXX vs. Placebo in the Treatment of Insomnia Associated with Generalized Anxiety Disorder (GAD) when used concomitantly with XXXXXX.”-2006 Avera Protocol XXXXXX-XXX-“A Phase2, Double-B, Placebo-Controlled Trial to Investigate the Safety and Efficacy of XXXXX in Subjects with Social Anxiety Disorder”-2006 Sepracor Protocol XXX-XXX-“The Efficacy of XXXXXXXXX mg as Adjunctive Therapy in Subjects with Insomnia Related to Generalized Anxiety Disorder”-2005 Forest Protocol XXX-XX-XX – “Fixed Dose Comparison of XXXXXXXXXXXX Combination in Adult Patients with Major Depressive Disorder.” - 2005 Cephalon Protocol XXXXX/XXXX/XX/XX – “A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety and Efficacy of XXXXXXXX© Treatment (up to XXmg/day) in Adults With Generalized Anxiety Disorder” – 2005 Cephalon Protocol XXXXX/XXXX/XX/XX – “A 10-Week, Randomized, Double-Blind, PlaceboControlled, Parallel-Group Study to Evaluate the Efficacy and Safety of XXXXXXXX® at X, X, and XXmg/day in the Treatment of Adults With Generalized Anxiety Disorder.” - 2004 GlaxoSmithKline Protocol XXXXXX – “A Twelve-week, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group, Active controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of XXXXXXXXX XXXXXXXXXXXX Extended-release (XXXXXXXXXX™ XX, XXXmg/day) and Extended-release XXXXXXXXXX (XXXXXXX XX, XX-XXXmg/day) in Subjects with Major Depressive Disorder.” – 2004 Organon Protocol X-XXXX – “A Multicenter, randomized, double-blind, double dummy, group comparative trial to compare the effects of XXXXXXXX and XXXXXX continuous combined XXXXXXXXX/XXXXXXXXXXXXXX on the vaginal bleeding pattern, sexual desire and arousal in post menopausal women with sexual dysfunction.” – 2004 Segraves, MD Protocol #XXXX-XXX. – “ A Multicenter, Double-Blind, Placebo-Controlled study of XXXXXXXXX XX in females with orgasm disorder.” - 2004 Fabre-Kramer Protocol – “A Double-Blind, Multicenter, Randomized, Placebo-Controlled Efficacy and Safety Study of XXX XXXXX XX in Subjects with Major Depressive Disorder.” - 2003 Eli Lilly Protocol XXX-XX-XXXX – An Open-Label Study to Evaluate the Efficacy and Safety of XXXXXXXXX Administered “On Demand” to Men of Various Populations with Erectile Dysfunction. – 2003 GlaxoSmithKline Protocol XXX-XXXXX – “A Randomized, Double-Blind, Parallel-Group, placeboControlled Fixed Dose Study Evaluating Efficacy and Safety of XXXXXXXXXX XX in Elderly Outpatients Diagnosed with Major Depressive Disorder.” - 2003 GlaxoSmithKline Protocol XXXXXXXX – “A Multicenter, Double-Blind, Randomized, PlaceboControlled Comparison of the Effects of Sexual Functioning of Extended-Release XXXXXXXXX XXXXXXXXXXXX )XXX-XXXmg) and XXXXXXXXXXXX (XX-XXmg) in Outpatients with Moderate to Severe Major Depression over and Eight-Week Treatment Period.” - 2003 GlaxoSmithKline Protocol XXXXXXXXX – “A Multicenter, Randomized, Double-Blind, ParallelGroup, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of 9 Once Daily Oral XXXXXXXX (XX-XX-XXmg) Versus Placebo in Subjects with Major Depressive Disorder Over an Eight-Week Treatment Period.” – 2003 Merck Protocol XXX-XX – “A Double-Blind, Multicenter, Placebo-Controlled Study of X-XXXXXX Gel Extrusion Module (XXX) X.X mg b.i.d to X.X mg b.i.d Versus XXXXXXXXX in the Treatment of Outpatients with Generalized Anxiety Disorder.” - 2002 Pharmacia & Upjohn Protocol XXXX-XXXX-XXX –“A 12 week randomized Double-Blind XXXXXXX-and XXXXXXXXX-Controlled Fixed-Dose Parallel-Group Multicenter Study for Generalized Anxiety Disorder”. – 2002 Pharmacia & Upjohn Protocol XXXX-XXXX-XXX – “ A 5 month open-label study on XXXXXXXXXXX in the treatment of Generalized Anxiety Disorder”. - 2002 GlaxoSmithKline Protocol XX-XXXXXX-XXXX – “A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating Efficacy and Safety of XX-XXXXXXX (XXmg/day and XXmg/day) and XXXXXXXXXX (XXmg/day) in Patients with Major Depressive Disorder”. – 2001 Merck Protocol XXX-XX –“A Worldwide, Multicenter, Double-Blind, Parallel, Acitive-Controlled, Long Term Safety Study of XX-XXXX in Outpatients with Major Depressive Disorder”. – 2001 Ortho-McNeil Protocol XXXX-XXX – “A 12-week, Multi-center, randomized, double-blind, placebo controlled, parallel group study of XXXXXX-XX in subjects with Bipolar Disorder Type 1”. -2001 Pfizer Protocol XXX-XXX-XXX – “A 6-week, Double-Blind, Randomized, Multicenter, Fixed-Dose, Placebo-Controlled Study of XXXXXXXXX, Dosed Twice a Day in Patients With Generalized Anxiety Disorder”. - 2001 Investigator Initiated study – “Double-Blind Placebo Controlled Study of XXX-XXXXXXX for Serotonergic Antidepressant Associated Sexual Dysfunction in Women”. 2001 Investigator Initiated study on a new therapy for HSDD. -2001 Merck – “A Double-Blind, Multicenter, Placebo and Active-Controlled Acute and Extension Study of XX-XXXX in the Treatment of Patients with Major Depressive Disorder With Melancholic Features”. 2001 An Eli Lilly study on a new medication for Major Depression. - 2000 Novartis Protocol XXXXXXX- “A Double-Blind, Randomized, Parallel-Group, Active And Placebo Controlled Study to Evaluate Safety and Efficacy of XXXXXXX in Patients with Social Phobia. – 2000 TAP Pharmaceutical Products Inc. Protocol XXX-XXX-XX-XXX – “A Phase II Randomized, Multicenter, Placebo and Active Controlled Study of XXXX XXX-XXX In Subjects With Major Depressive Disorder.” – 2000 Parke-Davis Protocol XXXX-XXX – “An 8-Week, Double-Blind, Randomized, Multicenter, FlexibleDose, Placebo-Controlled Study of XXXXXXXXX in Patients With Panic Disorder.” - 2000 Parke-Davis Protocol XXXX-XXX – “A 6-Week, Double Blind, Randomized, Multicenter, FlexibleDose, Placebo-Controlled Study of XXXXXXXX In Patients With Generalized Anxiety Disorder – 2000 A Eli Lilly study on a combination therapy for treatment resistant depression” – 1999 A Eli Lilly study on a new medication for depression” – 1999 A Eli Lilly study on a pharmacological treatment of antidepressant associated sexual dysfunction” – 1999 10 Pharmacia & Upjohn Protocol X-XXXX-XXXX – “XXXXXXXXXX vs. Placebo Double-Blind Treatment of Major Depressive Disorder Resistant to XXXXXXXXXX” – 1999 Pharmacia & Upjohn Protocol XXXXXXXXXXX-XXX – “Open-Label XXXXXXXXXX Rescue and Continuation Therapy” – 1999 Glaxo Wellcome Protocol XXXXXXXX - “A Randomized, Multicenter, Double-Blind, PlaceboControlled, Fixed-Dose 7-Week Evaluation of the Efficacy and Safety of XXXXXXXXXXX in Treatment of a Major Depressive Episode in Unipolar Depressed Patients” - 1998 SmithKline Beecham Protocol XXX XXXXXX- “A Randomized, Double-Blind, Placebo-Controlled, Flexible Dosage Trial to Evaluate the Efficacy and Tolerability of XXXXXXXXXX in Patients with Generalized Anxiety Disorder” - 1998 Glaxo Wellcome Protocol XXXXXXXX - “A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Safety and Efficacy and Effects on Sexual Functioning of XXXXXXXXXX (XXXXXXXXX XXXXXXXXXXXXX) XXXXXXXXX XXXXXXX (XX) and XXXXXXXXXX in Outpatients with Moderate to Severe Recurrent Major Depression” - 1998 Glaxo Wellcome Protocol XXXXXXXX - “A Multicenter Single-Blind Study of XXXXXXXXXX (XXXXXXXXX XXXXXXXXXXXXX) XXXXXXXXX XXXXXX (XX) in Non-Depressed Females with Hypoactive Sexual Desire Disorder (HSDD)” - 1998 Forest Laboratories, Inc. and Parke-Davis - “XXXXXX (XXXXXXXXX XXX) Clinical Experience Trial (Easy Access to Symptom Evaluation).” - 1998 Pharmacia & Upjohn Protocol XX-XXXX-XXX - “XXXXXXXXXX (XXX_XXXXXXX) Versus Placebo and XXXXXXXXXX in a Controlled, Randomized, Double-Blind, Multicenter Study of Treatment in Major Depressive Disorders” - 1998 Glaxo Wellcome Protocol No. XXXXXXXX - “A Multicenter Placebo-Controlled Study of XXXXXXXXXX (XXXXXXXXX XXXXXXXXXXXXX) XXXXXXXXX XXXXXXX (XX) for the Prevention of Relapse/Recurrence in Subjects Whose Depression Responded to Treatment With XXXXXXXXXX SR” - 1998 Pfizer, Inc. Protocol No. XXX-XXX - “A Multicenter, Randomized, Open Label, Comparative, Study of the Safety, Tolerability and Efficacy of XXXX XXXXXXXXXXX for Long Term Treatment of Subjects with Acute Migraine” - 1997 Pfizer, Inc. Protocol No. XXX-XXX - “A Multicenter, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of Escalating the Dose of XXXX XXXXXXXXXX in Subjects with Acute Migraine” - 1997 Pfizer, Inc./Eisai America, Inc. Protocol No. XXXXX-XXXX-XXX - “An Open Label, Multicenter Clinical Trial Evaluating the Safety and Efficacy of XXXXXXXX XXXXXXXXXXXXX (XXXXX) in Patients with Alzheimer’s Disease” - 1996 - 1997 Glaxo Wellcome Protocol No. XXXXXXXX - “A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Effects on Sexual Functioning of XXXXXXXXXX (XXXXXXXXX XXX) XXXXXXXXX XXXXXXX and XXXXXXXXXXX in Outpatients with Moderate to Severe Recurrent Major Depression” - 1996 - 1997 Bristol-Myers Squibb Protocol No. XXXXX-XXX XXXXXXXX X- "A Prospective, Multicenter, OpenLabel Study of XXXXXX (XXXXXXXXX XXX) Augmentation Therapy of XXXXXXX (XXXXXXXXXX XXX) in the Management of Patients with Symptoms of Depression in General Psychiatric Practices" - 1994 - 1995 Bristol-Myers Squibb Protocol No. XXXXX-XXX - "A Prospective, Multicenter, Open-Label Study of XXXXXXX (XXXXXXXXXX) in the Management of Patients with Symptoms of Depression in General Psychiatric Practices" - 1994 - 1995 11 Burroughs Wellcome Protocol XXX - "The Safety and Efficacy of XXXXXXXXXX XXXXXXXX XXXXXXX and XXXXXXXXXX in Depressed Outpatients" - 1994 Burroughs Wellcome Protocol XXX - "Safety Surveillance Study for XXXXXXXXXX XXXXXXXXX XXXXXXX" - 1993-1994 SmithKline Beecham Protocol XXX - "A Randomized, Comparative, Open-Label Study of XXXXXXXXXX in the Treatment of Depression as Used in a Clinical Practice Setting" - 1993 Pfizer Protocol X-XXXX - "Multicenter Trial to Evaluate the Efficacy and Safety of XXXXXXXXXX in the Treatment of Major Depression" - 1992 Burroughs Wellcome Protocol XXX - "Prospective Open Evaluation of the Seizure Incidence with XXXXXXXXX XXXXXXXXXXXXX" - 1988 Merrell-Dow Protocol - XXXXXXXXX: Smoking Termination Aid, 1984 AV MATERIALS BOOK IN PROGRESS : “I Sit With My Back to the Wall: Voices of Trauma:Voices of Healing.” A book for Combat Veterans and those who care about and for them….Written with Rev Dr. Chrys Parker Videotape for Physicians Recognizing Sexual Dysfunction in Depression Self Help Videotapes Headache, Depression, Anxiety, Alcoholism, Divorce, Sexual Abuse, Helping Your Child Succeed, Panic Disorder, Menopause, Attention Deficit Disorder, Men Who Batter, Affairs, Alcoholism in Elderly, High-tech Psychiatry, Sandwich Generation, Keeping Romance Alive, Elderly Alcoholism, Teen-age Drinking One hour PBS (KLRN TV) specials: Teen-age Drinking, Depression, Anxiety and Panic Disorder, Alzheimer’s Disease Human Sexuality Four part audio tape cassette series published by Audio-Digest and The American Psychiatric Association Sex and Recovery, A videotape distributed by Hazelden Recovery Center Modern Day ECT Videotape produced by Education Department, Southwest Texas Methodist Hospital, San Antonio, Texas, 1980 VD: It's Your Problem 16 mm and Videotape, Academy of Health Sciences Television Division, H.A. Croft, Technical Advisor and Producer Contraception: Alternatives for Today 16 mm Film and Videotape (used in Army), Winner of four first place awards, Academy of Health Sciences Television Division, H.A. Croft, Technical Advisor and Producer 12 POTENTIAL CONFLICT OF INTEREST INFORMATION HARRY CROFT, M.D. 2011 RESEARCH GRANTS to Croft Group Research Center Boehringer-Ingelheim, Bristol-Myers-Squibb, Cephalon, Forest, GlaxoSmithKline, Eli Lilly, Labopharm, Merck, Organon, Otsuka, Pfizer, Sanofi-Aventis, Takeda SPEAKING HONORARIA in past 5 years: Astra Zeneca, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Eli Lilly, Angenlini-Labopharm, Pfizer, SanofiAventis, Wyeth CONSULTANT in past 5 years: Forest, GlaxoSmith Kline, Eli Lilly, Pfizer ADVISORY BOARD in past 5 years: GlaxoSmithKline, Lilly, Pfizer OTHER FINANCIAL INTEREST (or Family): None Last revision: 07/27/2011 13